Duke University Medical Center
Durham, North Carolina, 27705, United States
NCT Number: NCT02472561
The purpose of this study is to understand the effects that a three month lifestyle-based mobile health (mHealth) peripheral artery disease (PAD) prevention program will have on improving physical activity, fitness, important PAD risk factors and quality of life (QOL) in patients with PAD.
By testing a novel mHealth intervention focused on lifestyle modification, this trial will address a critical evidence gap in the care of PAD patients. PAD patients are not eligible for cardiac rehabilitation and therefore struggle with unhealthy lifestyles, and these patients currently have no lifestyle-based care strategies to help them. The results of this study have the potential to lead to new sustainable and resource-efficient, lifestyle-based preventive care strategies for patients with stable PAD.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Durham, North Carolina, 27705, United States
This is a single-center, randomized trial designed to examine the hypothesis that a lifestyle-based mHealth peripheral artery disease (PAD) prevention program will improve physical activity, fitness, important PAD risk factors and quality of life (QOL).
The investigators may enroll up to 55 men and women being evaluated for leg pain from Duke PAD cardiovascular clinics or after lower extremity angioplasty in the Duke catheterization laboratory. Of the 55 men and women volunteers who may be initially consented, the investigators anticipate a portion (potentially 20%) may drop out during the study timeline, and approximately 45 are expected to complete this study. Following informed consent and baseline testing, the participants will be randomized (1.25:1.00) into either a mHealth (N=25) or usual care group (N=20) [for comparison] for a 12-week period. All patients will be evaluated for walking ability on a treadmill test, quality of life questionnaires, health literacy related to PAD and the most important risk factors specific to PAD (blood glucose if diabetic, daily physical activity and blood pressure).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.
Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.
Other names: Diabetics Only
Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.
Time frame: Baseline and 12-week
peak VO2 mL/kg/min
Time frame: 12-week
Patient Satisfaction Survey
Time frame: 12-week
Patient Satisfaction Survey
Time frame: Baseline and 12-week
Steps, time and distance per week
Time frame: Baseline and 12-week
Ratio of height to weight
Time frame: Baseline and 12-week
Fasting Plasma Glucose and Hemoglobin A1-C
Time frame: Baseline and 12-week
Time frame: Baseline and 12-week
Time frame: Baseline and 12-week
Time frame: Baseline and 12-week
Time frame: Baseline and 12-week
Duke University
Other
Verizon mHealth Solution for Elderly Underserved Patients With Peripheral Artery Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT04751890
Arterial Occlusive Diseases, Arteriosclerosis
Ferrara, Italy
View Trial DetailsNCT04083456
Amputation, Arterial Occlusive Diseases
Aurora, Colorado, United States
View Trial DetailsNCT04333615
Arterial Occlusive Diseases, Arteriosclerosis
São Paulo, Brazil
View Trial Details